• Explore /
  • Poster
  • / First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).

First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).

Abstract Video & Slides Poster

Authors

Maria Reig

Maria Reig

Hospital Provincial Clinic de Barcelona, Barcelona, Spain

Maria Reig , T.R. Jeffry Evans , Hong Jae Chon , Ho Yeong Lim , Min-Hee Ryu , Do Young Kim , Teresa Macarulla , Carlos Gomez-Martin , Victor Moreno , Beate Haugk , Thomas Ness , Pia Baumann , Sujata Bhoi , Karin Tunblad , Hans Wallberg , Fredrik Oberg , Jeong Heo , Malene Jensen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03781934

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 476)

DOI

10.1200/JCO.2024.42.3_suppl.476

Abstract #

476

Poster Bd #

C1

Abstract Disclosures

Similar Posters

First Author: Ghassan K. Abou-Alfa

First Author: Yongkang Xu

First Author: Lorenza Rimassa

First Author: Takeshi Terashima